SCHEMBL1490958

SCHEMBL1490958

O=c1[c]cc2ccc(O)cc2o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA9 Q16790 4/20 0.56
KDM4E B2RXH2 4/20 0.56
MEN1 O00255 4/20 0.56
GLA P06280 4/20 0.56
GAA P10253 4/20 0.56
KMT2A Q03164 4/20 0.56
CA12 O43570 3/20 0.56
ALDH1A1 P00352 3/20 0.56
HPGD P15428 3/20 0.56
CA1 P00915 2/20 0.56
MCL1 Q07820 2/20 0.56
TDP1 Q9NUW8 2/20 0.56
AKR1B1 P15121 1/20 0.56
CASP1 P29466 1/20 0.56
CASP7 P55210 1/20 0.56
HSD17B10 Q99714 1/20 0.56
ERAP1 Q9NZ08 1/20 0.56
HSD17B3 P37058 1/20 0.50
FLT3 P36888 1/20 0.49
ESR2 Q92731 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6031307 0.74 ALDH1A1 (0.60) CA9KDM4EMEN1GLAGAA
SCHEMBL1258966 0.73 KDM4E (0.64) CA9KDM4EMEN1GLAGAA
Umbelliferone SCHEMBL29396070 0.72 CA9 (1.00) CA9KDM4EMEN1GLAGAA
SCHEMBL25909 0.72 CA12 (0.48) CA9KDM4EGLAGAACA12
Umbelliferone SCHEMBL29624448 0.72 CA9 (1.00) CA9KDM4EMEN1GLAGAA
Umbelliferone SCHEMBL22018 0.72 CA9 (1.00) CA9KDM4EMEN1GLAGAA
Umbelliferone SCHEMBL11137587 0.72 CA9 (1.00) CA9KDM4EMEN1GLAGAA
Umbelliferone SCHEMBL2767044 0.71 CA9 (0.96) CA9KDM4EMEN1GLAGAA
Umbelliferone SCHEMBL27915972 0.71 CA9 (0.96) CA9KDM4EMEN1GLAGAA
Umbelliferone SCHEMBL307982 0.71 CA9 (0.96) CA9KDM4EMEN1GLAGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11987598-B2 E-selectin antagonist compounds, compositions, and methods of use GLYCOMIMETICS, INC. (US) 2024-05-21 US disclosed
US-20230097694-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GLYCOMIMETICS, INC. (US) 2023-03-30 US disclosed
US-11332491-B2 E-selectin antagonist compounds, compositions, and methods of use GLYCOMIMETICS, INC. (US) 2022-05-17 US disclosed
US-20210017215-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GLYCOMIMETICS, INC. (US) 2021-01-21 US disclosed
US-10766916-B2 E-selectin antagonist compounds, compositions, and methods of use GLYCOMIMETICS, INC. (US) 2020-09-08 US disclosed
US-20200157134-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GLYCOMIMETICS, INC. (US) 2020-05-21 US disclosed
EP-3296310-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GlycoMimetics, Inc. (US) 2018-03-21 EP disclosed
US-20180066006-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GLYCOMIMETICS, INC. (US) 2018-03-08 US disclosed
EP-2928476-B1 COMPOUNDS, COMPOSITIONS AND METHODS USING E-SELECTIN ANTAGONISTS FOR MOBILIZATION OF HEMATOPOIETIC CELLS GLYCOMIMETICS INC (US) 2018-02-14 EP disclosed
US-9867841-B2 Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells GLYCOMIMETICS, INC. (US) 2018-01-16 US disclosed
EP-2928476-A1 COMPOUNDS, COMPOSITIONS AND METHODS USING E-SELECTIN ANTAGONISTS FOR MOBILIZATION OF HEMATOPOIETIC CELLS GlycoMimetics, Inc. (US) 2015-10-14 EP disclosed
US-9109002-B2 E-selectin antagonist compounds, compositions, and methods of use GLYCOMIMETICS, INC. (US) 2015-08-18 US disclosed
US-20150110808-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GLYCOMIMETICS, INC. (US) 2015-04-23 US disclosed
WO-2015048616-A1 METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING MUCOSITIS GLYCOMIMETICS, INC. (US) 2015-04-02 WO disclosed
EP-2794626-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GlycoMimetics, Inc. (US) 2014-10-29 EP disclosed
WO-2014089269-A1 COMPOUNDS, COMPOSITIONS AND METHODS USING E-SELECTIN ANTAGONISTS FOR MOBILIZATION OF HEMATOPOIETIC CELLS GLYCOMIMETICS, INC. (US) 2014-06-12 WO disclosed
WO-2013096926-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE GLYCOMIMETICS, INC. (US) 2013-06-27 WO disclosed
US-20120214996-A1 COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2012-08-23 US disclosed
EP-2477698-A2 COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES Centre National de la Recherche Scientifique (FR) 2012-07-25 EP disclosed
WO-2011033115-A2 COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2011-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11332491-B2 E-selectin antagonist compounds, compositions, and methods of use SELE, SELPLG, SELP CA9 2265/4885KDM4E 3628/4885MEN1 1506/4885
US-20210017215-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SELE, SELPLG, SELP CA9 2265/4885KDM4E 3628/4885MEN1 1506/4885
US-10766916-B2 E-selectin antagonist compounds, compositions, and methods of use SELE, SELPLG, SELP CA9 2265/4885KDM4E 3628/4885MEN1 1506/4885
US-11987598-B2 E-selectin antagonist compounds, compositions, and methods of use SELE, SELPLG, SELP CA9 2265/4885KDM4E 3628/4885MEN1 1506/4885
US-20180066006-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SELE, SELPLG, SELP CA9 2265/4885KDM4E 3628/4885MEN1 1506/4885
US-20150110808-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SELE, SELPLG, SELP CA9 2265/4885KDM4E 3628/4885MEN1 1506/4885
US-20230097694-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SELE, SELPLG, SELP CA9 2265/4885KDM4E 3628/4885MEN1 1506/4885
US-20200157134-A1 E-SELECTIN ANTAGONIST COMPOUNDS, COMPOSITIONS, AND METHODS OF USE SELE, SELPLG, SELP CA9 2265/4885KDM4E 3628/4885MEN1 1506/4885
US-20120214996-A1 COMPOUNDS USEFUL AGAINST KINETOPLASTIDEAE PARASITES TST, PDXK, TBCB CA9 4862/4885KDM4E 854/4885MEN1 4710/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.